In vitro metabolism of imipramine by brain microsomes: Effects of inhibitors and exogenous cytochrome P450 reductase

Brain Research

Volumn 738, Issue 1, 1996, Pages 24-31

  Sequeira, David J ^a   Strobel, Henry W ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

antidepressant; brain; CYP2D; cytochrome P450; inhibitor; metabolism

Indexed keywords

ALPHA NAPHTHOFLAVONE; ANTIDEPRESSANT AGENT; CYTOCHROME P450 REDUCTASE; DRUG METABOLITE; IMIPRAMINE; KETOCONAZOLE; QUINIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN MICROSOME; CONTROLLED STUDY; DRUG METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030605155     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00759-7     Document Type: Article

References (36)

1. Schilter B., Omiecinski C.J. Regional distribution and expression modulation of cytochrome P450 and epoxide hydrolase mRNAs in the rat brain. Mol. Pharmacol. 44:1993;990-996.
2. Zaphiropoulos P.G., Wood T. Identification of the major cytochrome P450s of subfamily 2C that are expressed in brain of female rats and in olfactory lobes of ethanol treated male rats. Biochem. Biophys. Res. Commun. 193:1993;1006-1013.
3. Hodgson A.V., White T.B., White J.W., Strobel H.W. Expression analysis of the mixed function oxidase system in rat brain by polymerase chain reaction. Mol. Cell. Biochem. 120:1993;171-179.
4. Warner M., Köhler C., Hannson T., Gustafsson J. Regional distribution of cytochrome P450 in the rat brain: spectral quantitation and contribution of P450 b, e and P450 c, d. J. Neurochem. 50:1988;1057-1065.
5. Näslund B.M.A., Glaumann H., Warner M., Gustafsson J., Hansson T. Cytochrome P450 b and c in the rat brain and pituitary gland. Mol. Pharmacol. 33:1987;31-37.
6. Kawashima H., Strobel H.W. cDNA cloning of a novel rat brain cytochrome P450 belonging to the CYP2D subfamily. Biochem. Biophys. Res. Commun. 209:1995;535-540.
7. Komori M. A novel P450 expressed at the high level in the rat brain. Biochem. Biophys. Res. Commun. 196:1993;721-728.
8. Geng J., Strobel H.W. Identification of cytochromes P450 1A2, 2A1, 2C7, 2E1 in rat glioma C6 cell line by RT-PCR and specific restriction enzyme digestion. Biochem. Biophys. Res. Commun. 197:1993;1179-1184.
9. Geng J., Strobel H.W. Identification of inducible mixed function oxidase system in rat glioma C6 cell line. J. Neurochem. 65:1995;554-563.
10. Hansson T., von Bahr C., Marklund M., Svensson J.O., Inglelman-Sundberg M., Lundström Different regiospecificity in the hydroxylation of the antidepressant desmethylimipramine between rat brain and liver. Pharmacol. Toxicol. 71:1992;416-419.
11. Anadatheerthavarada H.K., Williams J.F., Wecker L. The chronic administration of nicotine induces cytochrome P450 in rat brain. J. Neurochem. 60:1993;1941-1944.
12. Anadatheerthavarada H.K., Shankar S.K., Ravindranath V. Rat brain cytochromes P450: catalytic, immunochemical properties and inducibility of multiple forms. Brain Res. 536:1990;339-343.
13. Kodalra H., Spector S. Transformation of thebaine to oripavine, codeine, and morphine by rat liver, kidney, and brain microsomes. Proc. Natl. Acad. Sci. USA. 85:1988;1267-1271.
14. Das M., Seth P.K., Dixit R., Mukhtar H. Aryl hydrocarbon hydroxylase of rat brain mitochondria: properties of, and effect of inhibitors and inducers on, enzyme activity. Arch. Biochem. Biophys. 217:1982;1097-1106.
15. Sequeira D.J., Strobel H.W. High-performance liquid chromatographic method for the analysis of imipramine metabolism in vitro by liver and brain microsomes. J. Chrom. Biomed. Appl. 673:1995;251-258.
16. Knapp J.A., Dignam J.D., Strobel H.W. NADPH-cytochrome P450 reductase: circular dichroism and physical studies. J. Biol. Chem. 252:1977;437-443.
17. Dingell J.V., Sulser F., Gillette J.R. Species differences in the metabolism of imipramine and desmethylimipramine (DMI). J. Pharmacol. Ther. 143:1964;14-22.
18. Gum J.R., Strobel H.W. Purified NADPH cytochrome P450 reductase. Interaction with hepatic microsomes and phospholipid vesicles. J. Biol. Chem. 254:1979;4177-4185.
19. Wyss A., Gustafsson J., Warner M. Cytochromes P450 of the 2D subfamily in rat brain. Mol. Pharmacol. 47:1995;1148-1155.
20. Skjelbo E., Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br. J. Clin. Pharmacol. 34:1992;256-261.
21. Mimura M., Yamazaki H., Sugahara C., Hiroi T., Funae Y., Shimada T. Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes. Biochem. Pharmacol. 47:1994;1957-1963.
22. Brøsen K., Zeugin T., Meyer U.A. Role of P450IID6, the target of the sparteine-debrisoquine oxidation polymorphism, in the metabolism of imipramine. Clin. Pharmacol. Therap. 49:1991;609-617.
23. Kronbach T., Mathys D., Gut J., Catin T., Meyer U.A. High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P450 isozymes of human liver. Anal. Biochem. 162:1987;24-32.
24. Meyer U.A., Gut J., Kronbach T., Skoda C., Meier U.T., Catin T., Dayer P. The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P450 isozymes catalyzing bufuralol and mephenytoin oxidation. Xenobiotica. 16:1986;449-464.
25. Guengerich F.P., Dislterath L.M., Reilly P.E., Wolff T., Shimada T., Umbenhauer D.R., Martin M.V. Human-liver cytochromes P450 involved in polymorphisms of drug oxidation. Xenobiotica. 16:1986;367-378.
26. Dayer P., Kronbach T., Eichelbaum M., Meyer U.A. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1′-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency. Biochem. Pharmacol. 36:1987;4145-4152.
27. Fonne-Pfister R., Bargetzi M.J., Meyer U.A. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem. Biophys. Res. Commun. 148:1987;1144-1149.
28. Zeugin T.B., Brøsen K., Meyer U.A. Determination of imipramine and seven of its metabolites in human liver microsomes by a high-performance liquid chromatographic method. Anal. Biochem. 189:1990;99-102.
29. Birgersson C., Morgan E.T., Jörvall H., von Bahr C. Purification of a desmethylimipramine and debrisoquine hydroxylating cytochrome P450 from human liver. Biochem. Pharmacol. 49:1986;3165-3166.
30. Su P., Coutts R.T., Baker G.B., Daneshtalab M. Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line. Xenobiotica. 23:1993;1289-1298.
31. Lemoine A., Gautier J.C., Azoulay D., Kiffel L., Belloc C., Guengerich F.P., Maurel P., Beaune P., Leroux J.P. Major pathway of imipramine metabolism is catalyzed by cytochromes P450 1A2 and P450 3A4 in human liver. Mol. Pharmacol. 43:1993;827-832.
32. Jellinck P.H., Smith G., Newcombe A.M. Inhibition of hepatic aryl hydrocarbon hydroxylase by 3-methylcholanthrene, 7,8-benzoflavone and other inducers added in vitro. Chem. Biol. Interact. 11:1975;459-468.
33. Kinoshita N., Gelboin H.V. Aryl hydrocarbon hydroxylase and polycyclic hydrocarbon tumorigenesis: effect of the enzyme inhibitor 7,8-benzoflavone on tumorigenesis and macromolecule binding. Proc. Natl. Acad. Sci. USA. 69:1972;824-828.
34. Sheets J.J., Mason J. Ketoconazole: a potent inhibitor of cytochrome P450-dependent drug metabolism in rat liver. Drug Metab. Disp. 12:1984;603-606.
35. Bhamre S., Bhagwat S.V., Shankar S.K., Boyd M.R., Ravindranath V. Flavin-containing monooxygenase mediated metabolism of psychoactive drugs by human brain microsomes. Brain Res. 672:1995;276-280.
36. Bhamre S., Bhagwat S.V., Shankar S.K., Williams D.E., Ravindranath V. Cerebral flavin-containing monooxygenase-mediated metabolism of antidepressants in brain: immunochemical properties and immunocytochemical localization. J. Pharmacol. Exp. Ther. 267:1993;555-559.